Research programme: sickle cell disease therapeutics - CSL BehringAlternative Names: Haptoglobin - CSL Behring; Hemopexin - CSL Behring
Latest Information Update: 10 Dec 2015
At a glance
- Originator CSL Behring
- Mechanism of Action Haemoglobin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Sickle cell anaemia
Most Recent Events
- 10 Dec 2015 Early research in Sickle cell anaemia in USA (unspecified route)